Fortress Biotech, Inc. (FBIO)

NASDAQ: FBIO · IEX Real-Time Price · USD
0.730
+0.020 (2.77%)
Mar 21, 2023, 3:59 PM EDT - Market closed
2.77%
Market Cap 90.98M
Revenue (ttm) 77.62M
Net Income (ttm) -91.19M
Shares Out 127.14M
EPS (ttm) -2.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 515,380
Open 0.725
Previous Close 0.710
Day's Range 0.700 - 0.730
52-Week Range 0.480 - 1.530
Beta 1.96
Analysts Buy
Price Target 8.67 (+1,087.67%)
Earnings Date Mar 27, 2023

About FBIO

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intra... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 173
Stock Exchange NASDAQ
Ticker Symbol FBIO
Full Company Profile

Financial Performance

In 2021, FBIO's revenue was $68.79 million, an increase of 50.86% compared to the previous year's $45.60 million. Losses were -$64.70 million, 39.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for FBIO stock is "Buy." The 12-month stock price forecast is $8.67, which is an increase of 1,087.67% from the latest price.

Price Target
$8.67
(1,087.67% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Journey Medical Corporation to Participate in the 35th Annual ROTH Conference

SCOTTSDALE, Ariz., March 07, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage biopharmaceutical company that focuses on the development and c...

Other symbols: DERM
2 weeks ago - GlobeNewsWire

Fortress Biotech to Participate in Two March 2023 Investor Conferences

MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing o...

2 weeks ago - GlobeNewsWire

Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Results demonstrate the potential benefit of vaccinating donors with Triplex to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transplant

1 month ago - GlobeNewsWire

Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex

Phase 2 clinical trial planned to evaluate efficacy of Triplex-vaccinated donors to enhance protective CMV-specific T cell immunity in stem cell transplant recipients

1 month ago - GlobeNewsWire

Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

MIAMI, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...

1 month ago - GlobeNewsWire

Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

MIAMI, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...

1 month ago - GlobeNewsWire

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

NEW YORK, NY / ACCESSWIRE / January 31, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATX...

Other symbols: ATXI
1 month ago - Accesswire

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

SCOTTSDALE, Ariz., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”), a commercial-stage biopharmaceutical company that focuses on the d...

Other symbols: DERM
2 months ago - GlobeNewsWire

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Topline data expected in the first half of 2023 Topline data expected in the first half of 2023

Other symbols: DERM
2 months ago - GlobeNewsWire

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29

Phase 3, registrational studies remain on track for first half of 2023 topline data readout Phase 3, registrational studies remain on track for first half of 2023 topline data readout

Other symbols: DERM
3 months ago - GlobeNewsWire

Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors

MIAMI, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or...

3 months ago - GlobeNewsWire

Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa

MIAMI, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiar...

3 months ago - GlobeNewsWire

Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

MIAMI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...

3 months ago - GlobeNewsWire

Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

SCOTTSDALE, Ariz., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the developm...

Other symbols: DERM
3 months ago - GlobeNewsWire

Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Net revenue for the nine months of 2022 increased 17.5% period-over-period to $59.3 million

4 months ago - GlobeNewsWire

Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Revenue for the first nine months of 2022 increased 26% to $57.7 million versus the same period in 2021 of $45.6 million

Other symbols: DERM
4 months ago - GlobeNewsWire

Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022

Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET Company to host conference call to discuss financial results and provid...

Other symbols: DERM
4 months ago - GlobeNewsWire

Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on efficient...

5 months ago - GlobeNewsWire

Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences

SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and comme...

Other symbols: DERM
6 months ago - GlobeNewsWire

Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D.

Company also strengthens Board of Directors with addition of Stanford Professor Vibeke Strand, M.D., MACR, FACP Company also strengthens Board of Directors with addition of Stanford Professor Vibeke S...

6 months ago - GlobeNewsWire

Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

MIAMI, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and ...

6 months ago - GlobeNewsWire

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Topline data expected in the first half of 2023 Topline data expected in the first half of 2023

Other symbols: DERM
7 months ago - GlobeNewsWire

Fortress Biotech (FBIO) Reports Q2 Loss, Misses Revenue Estimates

Fortress Biotech (FBIO) delivered earnings and revenue surprises of -20% and 17.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research